curettage 发表于 2025-3-23 12:10:55

http://reply.papertrans.cn/83/8241/824096/824096_11.png

Mediocre 发表于 2025-3-23 17:09:27

http://reply.papertrans.cn/83/8241/824096/824096_12.png

Medley 发表于 2025-3-23 22:03:31

When to use red blood cell transfusions in cancer patients with solid tumours?,py and also whilst on supportive therapies (.). Red Blood Transfusion (RBT) is the most commonly used form of correction of anaemia worldwide and in the United Kingdom (U.K) alone over 3 million blood product transfusions are carried out each year (.).

A简洁的 发表于 2025-3-23 22:23:52

http://reply.papertrans.cn/83/8241/824096/824096_14.png

重叠 发表于 2025-3-24 05:50:12

http://reply.papertrans.cn/83/8241/824096/824096_15.png

shrill 发表于 2025-3-24 07:47:50

,rhEPO in anemic patients with solid tumors and chemotherapy — efficacy and safety,ends on the type and stage of malignant disease and the type and intensity of treatment. Important factors for transfusion requirement are the degree of anemia, the age of patients and the presence of additional disorders, particularly those of the cardiovascular and pulmonary system. In a retrospec

ironic 发表于 2025-3-24 12:56:35

Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia, associated physical, emotional, psychological, and social effects (.). The effects of CIA are perhaps most noticeable in the treatment of elderly cancer patients at increased risk of mortality, functional dependence, cognitive disturbances, falls, and cerebrovascular and cardiovascular effects (.).

Sad570 发表于 2025-3-24 18:15:46

http://reply.papertrans.cn/83/8241/824096/824096_18.png

ENDOW 发表于 2025-3-24 20:40:48

http://reply.papertrans.cn/83/8241/824096/824096_19.png

inchoate 发表于 2025-3-24 23:15:13

http://reply.papertrans.cn/83/8241/824096/824096_20.png
页: 1 [2] 3 4 5 6 7
查看完整版本: Titlebook: Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology; Scientific and Clini Mohammad Resa Nowrousian Book 2008Latest edition Spring